Five Pfizer drugs among first 27 now subject to Medicare inflation rebates, HHS says
The Department of Health and Human Services (HHS) on Wednesday unveiled the first set of 27 Part B prescription drugs, including five from Pfizer, that will be subject to Medicare inflation rebates because their prices rose faster than the rate of inflation.
Seniors receiving the physician-administered drugs beginning in April will have lower coinsurance for these drugs (listed below) and HHS said they may see their out-of-pocket costs for these drugs decrease by as much as $390 per average dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.